Patents by Inventor John A. Ritchie

John A. Ritchie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ex vivo organ care system
    Patent number: 11944088
    Abstract: The invention generally relates to systems, methods, and devices for ex vivo organ care. More particularly, in various embodiments, the invention relates to caring for a liver ex vivo at physiologic or near-physiologic conditions.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: April 2, 2024
    Assignee: TRANSMEDICS, INC.
    Inventors: Waleed H. Hassanein, Tamer I. Khayal, Ahmed Elbetanony, Jeff Barnes, Greg Ritchie, Richard Bringham, Mark Anderson, John Sullivan
  • Isoquinoline derivatives for use in treating GLUT1 deficiency syndrome
    Patent number: 11925632
    Abstract: The present invention relates to new agents useful for the prevention and/or treatment of GLUT1-DS and related methods using the same.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: March 12, 2024
    Assignee: GLIAPHARM SA
    Inventors: Pierre Magistretti, Sylvain Lengacher, Charles Finsterwald, Timothy John Ritchie
  • Methods and apparatus for reducing sputtering of a grounded shield in a process chamber
    Patent number: 11915917
    Abstract: Methods and apparatus for physical vapor deposition are provided herein. In some embodiments, a process kit shield for use in a physical vapor deposition chamber may include an electrically conductive body having one or more sidewalls defining a central opening, wherein the body has a ratio of a surface area of inner facing surfaces of the one or more sidewalls to a height of the one or more sidewalls of about 2 to about 3.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: February 27, 2024
    Assignee: APPLIED MATERIALS, INC.
    Inventors: Alan Ritchie, John C. Forster, Muhammad Rasheed
  • ISOQUINOLINE DERIVATIVES FOR USE IN TREATING GLUT1 DEFICIENCY SYNDROME
    Publication number: 20230102415
    Abstract: The present invention relates to new agents useful for the prevention and/or treatment of GLUT1-DS and related methods using the same.
    Type: Application
    Filed: December 29, 2020
    Publication date: March 30, 2023
    Inventors: PIERRE MAGISTRETTI, SYLVAIN LENGACHER, CHARLES FINSTERWALD, TIMOTHY JOHN RITCHIE
  • AUTOMATIC TRANSFER PLUG
    Publication number: 20220285978
    Abstract: A power management system for home, apartment, facility and building circuits includes a grid inter-active system comprising a cord, an electrical connection to an outlet, and a connection to an external power producing appliance. In addition, the system includes a communication or automatic interface associated with a system that detects power outages or other grid or time related event.
    Type: Application
    Filed: May 25, 2022
    Publication date: September 8, 2022
    Applicant: Joule Case Inc.
    Inventors: Alexander Livingston, John Ritchie
  • AUTOMATIC TRANSFER PLUG
    Publication number: 20210104911
    Abstract: A power management system for home, apartment, facility and building circuits includes a grid inter-active system comprising a cord, an electrical connection to an outlet, and a connection to an external power producing appliance. In addition, the system includes a communication or automatic interface associated with a system that detects power outages or other grid or time related event.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 8, 2021
    Inventors: Alexander Livingston, John Ritchie
  • AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS
    Publication number: 20190083474
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: November 15, 2018
    Publication date: March 21, 2019
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS
    Publication number: 20180078536
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: November 21, 2017
    Publication date: March 22, 2018
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists
    Patent number: 9849117
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: December 26, 2017
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • LIGATURES AND USE THEREOF
    Publication number: 20170319316
    Abstract: An apparatus for removal of an animal body part, the apparatus comprising a ligature applicator, the ligature applicator being configured to move a ligature between a first, extended state in which the ligature can be passed over the animal body part to a selected application position, and a second, retracted state in which the ligature applies a compressive force at the application position to restrict blood flow in the animal body part; and a substance applicator, the substance applicator being configured to deliver a substance to the animal.
    Type: Application
    Filed: November 24, 2015
    Publication date: November 9, 2017
    Applicants: 4C DESIGN LIMITED, MEAT & LIVESTOCK AUSTRALIA LIMITED
    Inventors: Robin SMITH, William MITCHELL, John RITCHIE, Thomas HARRIS, Michael ALDRIDGE, Michael ANUSAS, Mark PENVER, John TARGELL
  • AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS
    Publication number: 20170112814
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: January 4, 2017
    Publication date: April 27, 2017
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists
    Patent number: 9567343
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: February 14, 2017
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • Substituted quinazolinones as vanilloid antagonists
    Patent number: 9102653
    Abstract: The present specification relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: August 11, 2015
    Assignee: NOVARTIS AG
    Inventors: Timothy John Ritchie, Andrew James Culshaw, Christopher Thomas Brain, Edward Karol Dziadulewicz, Terance William Hart
  • AZA-BICYLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS
    Publication number: 20150183794
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 10, 2015
    Publication date: July 2, 2015
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists
    Patent number: 9012451
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: April 21, 2015
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie
  • QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS
    Publication number: 20140315932
    Abstract: The present specification relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Applicant: NOVARTIS AG
    Inventors: Timothy John RITCHIE, Andrew James CULSHAW, Christopher Thomas BRAIN, Edward Karol DZIADULEWICZ, Terance William HART
  • Quinazolinone derivatives useful as vanilloid antagonists
    Patent number: 8809528
    Abstract: The present invention relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form, as a vanilloid.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: August 19, 2014
    Assignee: Novartis AG
    Inventors: Timothy John Ritchie, Andrew James Culshaw, Christopher Thomas Brain, Edward Karol Dziadulewicz, Terance William Hart
  • Compounds
    Patent number: 8765743
    Abstract: The invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: July 1, 2014
    Assignee: Glaxosmithkline Intellectual Property Development Limited
    Inventors: Ian Robert Baldwin, Kenneth David Down, Paul Faulder, Simon Gaines, Julie Nicole Hamblin, Joelle Le, Christopher James Lunniss, Nigel James Parr, Timothy John Ritchie, Juliet Kay Simpson, Christian Alan Paul Smethurst
  • Benzpyrazol derivatives as inhibitors of PI3 kinases
    Patent number: 8658635
    Abstract: The invention is directed to certain novel compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: February 25, 2014
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Ian Robert Baldwin, Kenneth David Down, Paul Faulder, Simon Gaines, Julie Nicole Hamblin, Joelle Le, Christopher James Lunniss, Nigel James Parr, Timothy John Ritchie, John Edward Robinson, Juliet Kay Simpson, Christian Alan Paul Smethurst
  • Compounds
    Patent number: 8536169
    Abstract: The invention is directed to certain novel compounds directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: September 17, 2013
    Assignee: Glaxo Group Limited
    Inventors: Ian Robert Baldwin, Kenneth David Down, Paul Faulder, Simon Gaines, Joelle Le, Nigel James Parr, Timothy John Ritchie, Juliet Kay Simpson, Christian Alan Paul Smethurst